Karyopharm Therapeutics | KPTI - Operating Profit


Karyopharm Therapeutics reported $-17.84M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
AbbVie USD 4.73B 1.08B Mar/2026
Abbott USD 1.85B 399M Mar/2026
Amgen USD 3.83B 130M Mar/2026
AstraZeneca USD 7.11B 4.14B Mar/2026
BioCryst Pharmaceuticals USD 260.38M 230.79M Dec/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Eli Lilly USD 9.78B 792M Mar/2026
Enanta Pharmaceuticals USD -23.54M 98.15M Dec/2024
GlaxoSmithKline GBP 2.29B 856M Mar/2026
Incyte USD 324.17M 59.7M Mar/2026
J&J USD 6.62B 1.03B Mar/2026
Karyopharm Therapeutics USD -17.84M 13.44M Dec/2025
MacroGenics USD -12.1M 30.74M Dec/2025
Merck USD -1.88B 8.12B Mar/2026
Nektar Therapeutics USD -19.09M 15.26M Dec/2025
Novartis USD 4.24B 171M Mar/2026
Novartis USD 4.06B 521M Dec/2025
Pfizer USD 4.99B 340M Mar/2026
Regeneron Pharmaceuticals USD 744.8M 153.8M Mar/2026
Roche Holding CHF 9.56B 3.8B Dec/2025
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Takeda JPY -13.62B 182.44B Mar/2026
Tectonic Therapeutic USD -21.52M 374K Dec/2025
TG Therapeutics USD 34.8M 15.7M Mar/2026
Ultragenyx Pharmaceutical USD -216M 102M Mar/2026
Xencor USD -77.86M 24.23M Mar/2026